DE69316921D1 - Neue verwendungen für il-10 - Google Patents

Neue verwendungen für il-10

Info

Publication number
DE69316921D1
DE69316921D1 DE69316921T DE69316921T DE69316921D1 DE 69316921 D1 DE69316921 D1 DE 69316921D1 DE 69316921 T DE69316921 T DE 69316921T DE 69316921 T DE69316921 T DE 69316921T DE 69316921 D1 DE69316921 D1 DE 69316921D1
Authority
DE
Germany
Prior art keywords
new uses
alone
optionally
manufacture
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69316921T
Other languages
English (en)
Other versions
DE69316921T2 (de
Inventor
Robert Coffman
Vries Jan De
Waal Malefyt Rene De
Fiona Powrie
Donna Rennick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/932,900 external-priority patent/US5368854A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE69316921D1 publication Critical patent/DE69316921D1/de
Application granted granted Critical
Publication of DE69316921T2 publication Critical patent/DE69316921T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
DE69316921T 1992-08-20 1993-08-18 Neue verwendungen für il-10 Expired - Lifetime DE69316921T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US07/932,900 US5368854A (en) 1992-08-20 1992-08-20 Use of IL-10 to treat inflammatory bowel disease
US93341992A 1992-08-21 1992-08-21
US93346292A 1992-08-21 1992-08-21
US93395092A 1992-08-21 1992-08-21
PCT/US1993/007646 WO1994004180A2 (en) 1992-08-20 1993-08-18 Novel uses of il-4 and/or il-10, and antibodies against the same

Publications (2)

Publication Number Publication Date
DE69316921D1 true DE69316921D1 (de) 1998-03-12
DE69316921T2 DE69316921T2 (de) 1998-06-04

Family

ID=27506019

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69316921T Expired - Lifetime DE69316921T2 (de) 1992-08-20 1993-08-18 Neue verwendungen für il-10

Country Status (23)

Country Link
EP (2) EP0801951A3 (de)
JP (1) JP3494647B2 (de)
KR (1) KR0170037B1 (de)
CN (1) CN1090204A (de)
AT (1) ATE162947T1 (de)
AU (1) AU680628B2 (de)
CA (1) CA2142861C (de)
CZ (1) CZ283488B6 (de)
DE (1) DE69316921T2 (de)
DK (1) DK0671933T3 (de)
ES (1) ES2111769T3 (de)
FI (1) FI950697A (de)
GR (1) GR3026635T3 (de)
HK (1) HK1004326A1 (de)
HU (1) HU220103B (de)
IL (1) IL106725A (de)
MX (1) MX9305054A (de)
MY (1) MY111402A (de)
PL (1) PL307566A1 (de)
RU (1) RU2120802C1 (de)
SK (1) SK21195A3 (de)
TW (1) TW243415B (de)
WO (1) WO1994004180A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510719A (ja) * 1993-02-01 1996-11-12 ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用
CZ1497A3 (en) * 1994-07-05 1997-05-14 Steeno Res Group As Polypeptide, its use and pharmaceutical composition based thereon, a nucleotide sequence and antibody
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
DE69534265T2 (de) * 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
EP0756871A1 (de) * 1995-08-01 1997-02-05 Institut Pasteur Verwendung von pharmazeutischen Zusammensetzungen die eine wirksame Dosierung von Interleukin-10 enthalten, einem Analogen und/oder einem Agonisten für Interleukin-10
CN1216470A (zh) * 1996-04-17 1999-05-12 帕特里克·T·普伦德加斯特 脱氢表雄酮组合治疗方法
WO1998027997A1 (en) * 1996-12-20 1998-07-02 Magainin Pharmaceuticals Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
ATE259829T1 (de) * 1998-10-20 2004-03-15 Vlaams Interuniv Inst Biotech Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
ES2234564T3 (es) 1999-02-10 2005-07-01 Mitsubishi Pharma Corporation Compuestos de tipo amida y su uso en medicina.
PT2295968E (pt) * 1999-12-03 2013-01-09 Baxter Int Teste de pirogenicidade para utilização com sistemas automatizados de imunoensaio
EP1283722A1 (de) * 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Kombinierte verwendung von anti-zytokin-antikörpern oder antagonisten und anti-cd20 zur behandlung von b-zell-lymphomen
AU6158501A (en) 2000-05-12 2001-11-26 Beth Israel Hospital Compositions and methods for achieving immune suppression
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
PE20090047A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
AR050044A1 (es) 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
DK1880001T3 (da) 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
EP1885383B1 (de) 2005-05-31 2016-09-21 IAMS Europe B.V. Katzen probiotisches bifidobacterium
EP1931762B1 (de) * 2005-10-03 2012-12-05 Actogenix N.V. Verwendung eines eine entzündungshemmende verbindung produzierenden rekombinanten hefestamms bei der herstellung eines arzneimittels zur behandlung von colitis
NO346530B1 (no) * 2006-09-28 2022-09-26 Merck Sharp & Dohme Anvendelser av pegylert interleukin-10 (PEG-IL-10) for å forebygge metastaser av kreft eller tumor i lungene.
CN101711158A (zh) 2007-02-01 2010-05-19 爱默思公司 使用葡萄糖抗代谢物、鳄梨或鳄梨提取物减轻哺乳动物炎症和应激反应的方法
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US9943568B2 (en) * 2013-04-18 2018-04-17 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating cancer
EP3010527B1 (de) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Verfahren zur beurteilung der proteinidentität und -stabilität
PL3021873T3 (pl) 2013-07-18 2019-01-31 Xalud Therapeutics, Inc. Kompozycja do leczenia choroby zapalnej stawów
EP3038642A4 (de) 2013-08-30 2017-01-18 Armo Biosciences, Inc. Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
WO2017035232A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN114349858B (zh) * 2022-01-26 2022-07-01 优睿赛思(武汉)生物科技有限公司 抗人白介素-10高亲和力兔单克隆抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
CZ282523B6 (cs) * 1991-01-16 1997-07-16 Schering Corporation Iterleukin - 10 pro léčení nádorů, farmaceutický prostředek jej obsahující, jeho použití a způsob výroby
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair

Also Published As

Publication number Publication date
EP0671933B1 (de) 1998-02-04
HU9500467D0 (en) 1995-04-28
ES2111769T3 (es) 1998-03-16
EP0801951A3 (de) 1998-05-20
EP0801951A2 (de) 1997-10-22
RU95108330A (ru) 1996-11-27
WO1994004180A2 (en) 1994-03-03
JPH08500362A (ja) 1996-01-16
DE69316921T2 (de) 1998-06-04
WO1994004180A3 (en) 1994-06-09
IL106725A0 (en) 1993-12-08
ATE162947T1 (de) 1998-02-15
JP3494647B2 (ja) 2004-02-09
CZ283488B6 (cs) 1998-04-15
CA2142861C (en) 2000-08-15
CN1090204A (zh) 1994-08-03
CA2142861A1 (en) 1994-03-03
HU220103B (hu) 2001-10-28
AU680628B2 (en) 1997-08-07
DK0671933T3 (da) 1998-09-23
HUT70976A (en) 1995-11-28
SK21195A3 (en) 1996-10-02
MY111402A (en) 2000-04-29
FI950697A (fi) 1995-04-07
RU2120802C1 (ru) 1998-10-27
EP0671933A1 (de) 1995-09-20
FI950697A0 (fi) 1995-02-16
TW243415B (de) 1995-03-21
KR0170037B1 (ko) 1999-02-01
CZ44195A3 (en) 1995-10-18
HK1004326A1 (en) 1998-11-20
AU5010893A (en) 1994-03-15
GR3026635T3 (en) 1998-07-31
IL106725A (en) 2000-12-06
PL307566A1 (en) 1995-05-29
MX9305054A (es) 1994-02-28
KR950702841A (ko) 1995-08-23

Similar Documents

Publication Publication Date Title
DE69316921D1 (de) Neue verwendungen für il-10
ATA188592A (de) Alkyl-bisacylphosphinoxide, diese enthaltende zusammensetzungen und ihre verwendung
IL128425A0 (en) Taxane derivatives their preparation and pharmaceutical compositions containing them
FI941570A0 (fi) Katalyyttikoostumus
DE69033299D1 (de) Verwendung von Carnosolsäure wegen seiner anticarcinogenen und antiviralen Eigenschaften
DE3889197D1 (de) Klebstoff-Zusammensetzungen und diese Zusammensetzungen enthaltende Laminate.
FI942444A (fi) Terahydropyraanijohdannaisia
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
DE69402623D1 (de) Rostschutzzusammensetzung
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
DE69114184D1 (de) Harzzusammensetzung für Grundierung und Grundierungsmittel davon.
FI923751A (fi) Hexahydrobenso/f/kinolinoner
DE3863687D1 (de) Tinten-zusammensetzungen und deren zubereitung.
DE69300503D1 (de) Zusammensetzung für einen Dickschichtwiderstand.
DE3872764D1 (de) Tinten-zusammensetzungen und deren zubereitung.
DE59109007D1 (de) Zusammensetzung zur Regulierung der Darmflora
DE3778938D1 (de) Harzzusammensetzungen fuer beschichtungszwecke, ihre herstellung und diese enthaltende beschichtungsmassen.
IT1263170B (it) Composizione antiemorroidale
DE69003521D1 (de) Schmiermittelzusammensetzung und ihre Herstellung.
MX9203089A (es) Composicion para el tratamiento de esquisofrenia.
NO894231D0 (no) Belegningspreparat.
TR20688A (tr) Yatak olarak kullamlabilen kanepeler ve bunlarin acilip kapanmasini saglayan mekanizma tertibati
ES536881A0 (es) Mejoras introducidas en el objeto de la patente de invencion n. 516325.
ES546105A0 (es) Mejoras introducidas en el objeto de la patente de invecion n 516.822 por central unificada de tiempos para automoviles
ES1021355Y (es) Articulo para la organizacion personal tipo agenda.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition